Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (Blakemore 2010; Helb 2010).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Helb 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
From Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens (2011) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,973
The association for the advancement of medical instrumentation
(1974) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(74)90035-0 · Cited by 1,031
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525 · cited 1×
“tuberculosis detection (15), this assay was too complex and too prone to operator errors, sample cross-contamination, and biohazards for rapid near-patient use.”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 3×
“Truly rapid results for drug susceptibility tests are particularly important in the management of drug-resistant tuberculosis (13).”
BackgroundMicroscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Cited by
Items 101–200 of 940
Changing Concepts of “Latent Tuberculosis Infection” in Patients Living with HIV Infection
Lawn, S. D., Wood, R., & Wilkinson, R. J. (2010) · Clinical and Developmental Immunology · doi:10.1155/2011/980594 · Cited by 104
“However, simplified forms of newer generations of nucleic acid amplification tests have far greater sensitivity and are likely to represent a major step forward [60–62].”
BackgroundEnfermedades Infecciosas y Microbiología Clínica
Viasus, D., Antón, A., Pumarola, T., & Carratalà, J. (2016) · Cited by 90
Central nervous system complications of HIV infection.
Luetkemeyer, A. F., Havlir, D. V., & Currier, J. S. (2011) · Europe PMC (PubMed Central) · Cited by 91
Diagnosis of tuberculous pleural effusions: A review
Cascio, C. M. L., Kaul, V., Dhooria, S., Agrawal, A., & Chaddha, U. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106607 · Cited by 89
Managing latent tuberculosis infection and tuberculosis in children
Carvalho, I., Goletti, D., Manga, S., Silva, D. R., Manissero, D., & Migliori, G. B. (2018) · Pulmonology · doi:10.1016/j.rppnen.2017.10.007 · Cited by 88
“The newer GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) assay is a NAAT that detects M tuberculosis DNA and concomitant resistance to rifampicin.(50) The GeneXpert MTB RIF assay requires less training and infrastructure to perform and interpret than other commercially available molecular assays, produces results in…”
BackgroundEngström, A., Morcillo, N., Imperiale, B. R., Hoffner, S. E., & Juréen, P. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06664-11 · Cited by 92
Tadesse, M., Abebe, G., Abdissa, K., Aragaw, D., Abdella, K., Bekele, A., Bezabih, M., Apers, L., de Jong, B. C., & Rigouts, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137471 · Cited by 85
Rising to the challenge: new therapies for tuberculosis
Wong, E. B., Cohen, K. A., & Bishai, W. R. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.05.002 · Cited by 87
Wilson, M. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir146 · Cited by 85
A Handheld Point-of-Care Genomic Diagnostic System
Myers, F. B., Henrikson, R. H., Bone, J. M., & Lee, L. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070266 · Cited by 92
Rahman, A., Sahrin, M., Afrin, S., Earley, K. T., Ahmed, S., Rahman, S. M. M., & Banu, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152694 · Cited by 85
“Rifampicin resistance can be used as a surrogate marker for MDR-TB, as more than 90% of RIF-resistant isolates are also resistant to INH, another potent first-line anti-TB drug [4, 6, 7].”
BackgroundSekyere, J. O., Maphalala, N., Malinga, L. A., Mbelle, N. M., & Maningi, N. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-53086-5 · Cited by 91
Harnessing CRISPR Effectors for Infectious Disease Diagnostics
Bhattacharyya, R. P., Thakku, S. G., & Hung, D. T. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00170 · Cited by 92
Trauner, A., Borrell, S., Reither, K., & Gagneux, S. (2014) · Drugs · doi:10.1007/s40265-014-0248-y · Cited by 94
“Their recommendation for Xpert MTB/RIF to replace microscopy in HIV-positive patients, patients suspected of MDR-TB, and those suspected of TB meningitis follows its successful implementation in many countries [31, 32].”
BackgroundMéndez‐Samperio, P. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12567 · Cited by 96
Campelo, T. A., de Sousa, P. R. C., Nogueira, L. D. L., Frota, C. C., & Antas, P. R. Z. (2021) · Access Microbiology · doi:10.1099/acmi.0.000245 · Cited by 96
Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy
Lawn, S. D., & Meintjes, G. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.21 · Cited by 90
Jain, P., Hartman, T. E., Eisenberg, N., O'Donnell, M. R., Kriakov, J., Govender, K., Makume, M., Thaler, D. S., Hatfull, G. F., Sturm, A. W., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06192-11 · Cited by 80
“However, Xpert MTB/RIF detects only rifampin resistance (Rif) and relies on the fact that almost all clinical Rif strains identified to date harbor one of three specific point mutations (2, 7, 8, 21, 28, 44).”
BackgroundHepple, P., Ford, N. P., & McNerney, R. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0617 · Cited by 81
Simple System for Isothermal DNA Amplification Coupled to Lateral Flow Detection
Roskos, K., Hickerson, A. I., Lu, H., Ferguson, T. M., Shinde, D. N., Klaue, Y., & Niemz, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069355 · Cited by 87
Eldin, G. S. S., Fadl-Elmula, I. M., Ali, M. S., Ali, A. B., Salih, A. L. G., Mallard, K., Bottomley, C., & McNerney, R. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-219 · Cited by 81
“predict MDR-TB when using the new generation of molecular tests such as the Xpert MTB/RIF (Cepheid, California, USA) [29] which rely on detection of mutations in a sub unit of the RNA polymerase gene.”
MethodClinical management of tuberculosis and HIV-1 co-infection
Schutz, C., Meintjes, G., Almajid, F. M., Wilkinson, R. J., & Pozniak, A. (2010) · European Respiratory Journal · doi:10.1183/09031936.00110210 · Cited by 90
“18 negative culture-positive cases [106] and is under extensive evaluation.”
BackgroundDiagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF
Lombardi, G., Gregori, V. D., Girometti, N., Tadolini, M., Bisognin, F., & Monte, P. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176186 · Cited by 89
Miller, M. B., Popowitch, E. B., Backlund, M. G., & Ager, E. P. C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05212-11 · Cited by 77
“CA) and Xpert MTB/RIF assay were described in detail previously (3, 4, 8).”
BackgroundMethodDrobniewski, F. A., Nikolayevskyy, V., Михайловна, Б. Я., Bang, D., & Papaventsis, D. C. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0180 · Cited by 90
Advances in the molecular diagnosis of tuberculosis: From probes to genomes
Machado, D., Couto, I., & Viveiros, M. (2018) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2018.11.021 · Cited by 83
Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries
Niemz, A., & Boyle, D. S. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.71 · Cited by 83
Balcha, T. T., Sturegård, E., Winqvist, N., Skogmar, S., Reepalu, A., Jemal, Z. H., Tibesso, G., Schön, T., & Björkman, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085478 · Cited by 71
“This gene is probed with molecular beacons to detect rifampicin resistance mutations which can be used as surrogate markers for multidrug-resistant TB (MDR-TB) [19].”
Steiner, I., Schmutzhard, E., Sellner, J., Chaudhuri, A., & Kennedy, P. G. E. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03808.x · Cited by 83
“Higher yield of positive result in quantitative RT-PCR test has been observed after using CSF filtrate as compared with CSF sediment [69], and a novel RT-PCR-based rapid detection method (Xpert MTB/RIF assay), that is relatively easy to use, has shown great promise in identifying drug-resistant Mycobacteria in pulmona…”
MethodDiagnostic Accuracy and Turnaround Time of the Xpert MTB/RIF Assay in Routine Clinical Practice
Kwak, N., Choi, S. M., Lee, J., Park, Y. S., Lee, C., Lee, S., Yoo, C., Kim, Y. W., Han, S. K., & Yim, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077456 · Cited by 74
“TB detection using the Xpert MTB/RIF assay is affected by the number of colonies in the sample [10].”
MethodCurrent Prospects for the Fluoroquinolones as First-Line Tuberculosis Therapy
Takiff, H. E., & Guerrero, E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00695-11 · Cited by 74
“Curtailing the use of FQs to treat respiratory symptoms when TB cannot be effectively excluded by keen clinical judgment or a highly sensitive diagnostic test (36) would reduce concerns about the development of resistance and also eliminate the delays in initiating TB therapy that occur when FQs are inadvertently admi…”
BackgroundPandey, P., Pant, N. D., Rijal, K. R., Shrestha, B., Kattel, S., Banjara, M. R., Maharjan, B., & Rajendra, K. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169798 · Cited by 74
Lawn, S. D., Kerkhoff, A. D., Vogt, M., Ghebrekristos, Y. T., Whitelaw, A. C., & Wood, R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1039 · Cited by 73
Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - Report from a developing country
Yusuf, N. W., Iram, S., Zeenat, A., Hussain, S., & Aslam, M. (2014) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.311.6970 · Cited by 73
Yan, L., Xiao, H., & Zhang, Q. (2016) · Tuberculosis · doi:10.1016/j.tube.2015.11.005 · Cited by 72
New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis
O’Grady, J., Maeurer, M. J., Mwaba, P., Kapata, N., Bates, M., Höelscher, M., & Zumla, A. I. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283452346 · Cited by 72
Drobniewski, F. A., Nikolayevskyy, V., Maxeiner, H., Михайловна, Б. Я., Casali, N., Сергеевна, К. И., & Ignatyeva, O. A. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-190 · Cited by 78
Sowajassatakul, A., Prammananan, T., Chaiprasert, A., & Phunpruch, S. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-165 · Cited by 71
“tuberculosis and MDR-TB, respectively [2-7].”
Singh, U. B., Pandey, P., Mehta, G., Bhatnagar, A. K., Mohan, A., Goyal, V., Ahuja, V., Ramachandran, R., Sachdeva, K. S., & Samantaray, J. C. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149258 · Cited by 68
“5 genomes per reaction, and a clinical LOD of 131cfu/ml [2].”
BackgroundSensitivity‐Enhancing Strategies in Optical Biosensing
Kim, Y., Gonzales, J. M., & Zheng, Y. (2020) · Small · doi:10.1002/smll.202004988 · Cited by 70
Recent advances and challenges of biosensing in point-of-care molecular diagnosis
Chu, H., Liu, C., Liu, J., Yang, J., Li, Y., & Zhang, X. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.130708 · Cited by 72
Wei, Z., Zhang, X., Wei, C., Yao, L., Li, Y., Zhang, X., Xu, H., Jia, Y., Guo, R. H., Wu, Y. H., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4273-z · Cited by 69
Allahyartorkaman, M., Mirsaeidi, M. S., Hamzehloo, G., Amini, S., Zakiloo, M., & Nasiri, M. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-55112-y · Cited by 68
Xu, G., Liu, H., Jia, X., Wang, X., & Xu, P. (2021) · Tuberculosis · doi:10.1016/j.tube.2021.102083 · Cited by 71
Naidoo, P., Toit, E. D., Dunbar, R., Lombard, C. J., Caldwell, J., Detjen, A., Squire, S. B., Enarson, D. A., & Beyers, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103328 · Cited by 67
“The efficacy of both tests has been well established [7–12] and confirmed by systematic reviews [13–15].”
BackgroundMboowa, G., Namaganda, C., & Ssengooba, W. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-481 · Cited by 67
“…(Cepheid, USA) has revolutionalised the diagnosis of tuberculosis (TB) by simultaneously detecting the bacteria and resistance to rifampicin (rif) [1,2], one of the principal first-line anti-tuberculosis drugs, which inhibits DNA-directed RNA synthesis of Mycobacterium tuberculosis (MTB) proteins…”
Shah, M., Paradis, S., Betz, J., Beylis, N., Bharadwaj, R. S., Cáceres, T., Gotuzzo, E., Joloba, M. L., Mave, V., Nakiyingi, L., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz932 · Cited by 68
“Two rapid molecular tests, namely the Xpert MTB/RIF assay (Xpert; Cepheid) [3, 4] and the GenoType MTBDRplus (Hain Lifescience) are commercialized and used in some TB-endemic settings, but each has important limitations in addition to attributes.”
MethodXpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression
Hanrahan, C. F., Theron, G., Bassett, J., Dheda, K. U. J., Scott, L. E., Stevens, W. S., Sanne, I., & Rie, A. V. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2140oc · Cited by 73
“showed a strong correlation between the mean Xpert CT value of all five probes and CFU, with a detection limit of approximately 100 bacilli (10, 11).”
BackgroundTuberculosis assays: past, present and future
Chegou, N. N., Hoek, K. G. P., Kriel, M., Warren, R. M., Victor, T. C., & Walzl, G. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.23 · Cited by 70
Theron, G., Pooran, A., Peter, J., van Zyl-Smit, R., Kumar Mishra, H., Meldau, R., Calligaro, G., Allwood, B., Sharma, S. K., Dawson, R., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00145511 · Cited by 64
Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey
Dorman, S. E., Chihota, V. N., Lewis, J. J., Shah, M., Clark, D., Grant, A. D., Churchyard, G. J., & Fielding, K. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043307 · Cited by 65
“Xpert MTB/RIF (Cepheid, Sunnyvale, CA) is an integrated specimen processing and nucleic acid amplification-based test for detection of MTB and rifampin resistance-conferring mutations directly from sputum [12].”
MethodUllah, I., Shah, A. A., Basit, A., Ali, M., Khan, A., Ullah, U., Ihtesham, M., Mehreen, S., Mughul, A., & Javaid, A. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1745-2 · Cited by 66
“2 ml of inactivated specimen was transferred to the Xpert test cartridge and tested according to manufacturer's guide [4, 14].”
MethodDiagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Tunisia
Ghariani, A., Jaouadi, T., Smaoui, S., Mehiri, E., Marouane, C., Kammoun, S., Essalah, L., Driss, M., Messadi, F., & Slim-Saidi, L. (2015) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2015.05.011 · Cited by 65
Delhi Pediatric TB study group, Singh, S., Singh, A., Prajapati, S., Kabra, S. K., Lodha, R., Mukherjee, A., Singh, V., Hesseling, A. C., & Grewal, H. M. S. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0528-z · Cited by 65
“We are analyzing this isolate, to determine if the isolate has a unique mutation in rpoB gene which inhibited amplification of this gene [36].”
From Tradition to Innovation: Diverse Molecular Techniques in the Fight Against Infectious Diseases
Alsharksi, A. N., Sirekbasan, S., Tan, T. G., & Mustapha, A. (2024) · Diagnostics · doi:10.3390/diagnostics14242876 · Cited by 73
Howson, E. L. A., Armson, B., Madi, M., Kasanga, C. J., Kandusi, S., Sallu, R., Chepkwony, E. C., Siddle, A., Martin, P., Wood, J., et al. (2015) · Transboundary and Emerging Diseases · doi:10.1111/tbed.12451 · Cited by 66
“…are now available to lyophilize reagents, already tested in a number of LAMP (Boehme et al., 2007; Mair et al., 2013) and PCR assays (Siegmund et al., 2005; Aitichou et al., 2008; Helb et al., 2010; Takekawa et al., 2012), with benefits including improved stability, storage and transportability.”
BackgroundOu, X., Li, Q., Xia, H., Pang, Y., Wang, S., Zhao, B. T., Song, Y., Zhou, Y., Zheng, Y., Zhang, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094544 · Cited by 62
“To address the need for rapid and sensitive diagnosis of TB, a number of nucleic acid amplification assays have been invented [6,7,8]; however, they are still not routinely applied in developing countries due to their high cost, complicated procedures, insufficient laboratory facilities, and a shortage of skilled tech…”
BackgroundBarnard, D. A., Irusen, E. M., Bruwer, J. W., Plekker, D., Whitelaw, A. C., Deetlefs, J. D., & Koegelenberg, C. F. N. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0086-z · Cited by 62
“No cross-reactivity has been reported between Xpert MTB/RIF and multiple bacteria, viruses, fungi or mycobacteria species other than tuberculosis and should therefore not be the reason for false positive results [19, 20].”
BackgroundBergval, I., Sengstake, S., Brankova, N., Levterova, V., Abadía, E., Nino, T., Bablishvili, N., Akhalaia, M., Tuin, K., Schuitema, A. R. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043240 · Cited by 61
“tuberculosis by sequencing [20], reverse hybridisation to low-density arrays [21,22] or molecular beacons in a PCR reaction [23,24] has been extraordinarily successful.”
Ardizzoni, E., Fajardo, E., Saranchuk, P., Casenghi, M., Page, A., Varaine, F., Kosack, C., & Hepple, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144656 · Cited by 61
“In these cases repeating the test on a new sample may have produced a positive Xpert result; however, these results were not available, thus the proportion of cases detected by Xpert may be underestimated.[20] Secondly, Xpert negative, smear positive results could be due to the presence of non-tuberculosis mycobacteri…”
ResultEngel, N., Ochodo, E., Karanja, P. W., Schmidt, B., Janssen, R., Steingart, K. R., & Oliver, S. R. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014877.pub2 · Cited by 68
“We limited all searches to 2007 onward because the development of Xpert MTB/RIF, the first rapid molecular test in this review, was completed in 2009 and the first paper describing its clinical use was published electronically in 2009 (Helb 2010).”
BackgroundMethodvan’t Hoog, A. H., Cobelens, F., Vassall, A., van Kampen, S., Dorman, S. E., Alland, D., & Ellner, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082786 · Cited by 58
“The Xpert MTB/RIF assay [5] (Cepheid, Sunnyvale, CA, USA), hereafter referred to as Xpert, is the first NAAT endorsed by World Health Organization (WHO) for widespread use [6,7].”
MethodSelf-citationXpert MTB/RIF Assay as a Substitute for Smear Microscopy in an Intermediate-Burden Setting
Lee, H., Kee, S., Shin, J. H., Kwon, Y. S., Chun, S., Lee, J. H., Won, E. J., Choi, H., Kim, S. H., Shin, M., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201804-0654oc · Cited by 63
de Haas, P., Yenew, B., Mengesha, E., Slyzkyi, A., Gashu, Z., Lounnas, M., Tesfaye, E., Bedru, A., Tiemersma, E. W., Kremer, K., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00406-21 · Cited by 61
“The SOS stool processing procedure was conducted following the standard protocol for sputum processing for Xpert testing (16, 17) with a few minor modifications with regard to the volume of SR used, the duration of the last incubation step, and how to handle the SR-stool mixture when transferring the sample into the c…”
BackgroundMethodInfluentialShah, M., Ssengooba, W., Armstrong, D. T., Nakiyingi, L., Holshouser, M., Ellner, J. J., Joloba, M. L., Manabe, Y. C., & Dorman, S. E. (2014) · AIDS · doi:10.1097/qad.0000000000000264 · Cited by 59
“specificity for TB have been above 95% in some settings, and the test has been endorsed by the WHO for use in resource-constrained settings [9,10].”
MethodFace Mask Sampling for the Detection of Mycobacterium tuberculosis in Expelled Aerosols
Williams, C., Cheah, E. S. G., Malkin, J., Patel, H., Otu, J. K., Mlaga, K. D., Sutherland, J. S., Antonio, M., Perera, N., Woltmann, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104921 · Cited by 59
Biadglegne, F., Sack, U., & Rodloff, A. C. (2014) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-3-31 · Cited by 59
Chakravorty, S., Roh, S. S., Glass, J. S., Smith, L. E., Simmons, A. M., Lund, K., Lokhov, S. G., Liu, X., Xu, P., Zhang, G., et al. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.01771-16 · Cited by 59
“2A), yet for the XDR assay to be used as a reflex test for positive Xpert MTB/RIF assays, its ideal LOD should be roughly equivalent to the Xpert MTB/RIF assay LOD of 132 CFU/ml (24).”
Self-citationLau, S. K. P., Lee, K.-C., Curreem, S. O. T., Chow, F. W., To, K. K., Hung, I. F., Ho, D. T.-Y., Sridhar, S., Li, I. W. S., Ding, V. S. Y., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.01568-15 · Cited by 58
Molecular Logic Gates for DNA Analysis: Detection of Rifampin Resistance in M. tuberculosis DNA
Cornett, E. M., Campbell, E. A., Gulenay, G., Peterson, E., Bhaskar, N., & Kolpashchikov, D. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203708 · Cited by 61
Ng, B. Y. C., Xiao, W., West, N. P., Wee, E. J. H., Wang, Y., & Trau, M. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03121 · Cited by 63
Schnippel, K., Meyer‐Rath, G., Long, L., MacLeod, W., Sanne, I., Stevens, W. S., & Rosen, S. (2012) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2012.03028.x · Cited by 54
“Early reports on the Xpert MTB ⁄ RIF technology suggest that it was designed to be placed at patient-contact sites where nurses could provide treatment immediately upon diagnosis (Helb et al. 2010; Morris 2010; Boehme et al. 2011).”
BackgroundMethodChakravorty, S., Aladegbami, B. G., Thoms, K., Lee, J. S., Lee, E. G., Rajan, V., Cho, E.-J., Kim, H., Kwak, H., Kurepina, N. E., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02271-10 · Cited by 57
“tuberculosis with sensitivity close to that of culture and identifies the presence of rifampin resistance (19).”
BackgroundSelf-citationKhalil, K. F., & Butt, T. M. (2015) · PubMed · Cited by 57
Chipinduro, M., Mateveke, K., Makamure, B., Ferrand, R. A., & Gomo, E. (2016) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0357 · Cited by 57
Jaleta, K. N., Gizachew, M., Gelaw, B., Tesfa, H., Getaneh, A., & Biadgo, B. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s135935 · Cited by 57
“19 20–22 Most rifampin-resistant MTB-complex strains have mutations in an 81-base-pair region of the RPOB gene that encodes the RNA polymerase β -subunit.”
Early diagnosis with ultrasensitive ELISA
Ito, E., Iha, K., Yoshimura, T., Nakaishi, K., & Watabe, S. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.06.002 · Cited by 62
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa
Lawn, S. D., Harries, A. D., Meintjes, G., Getahun, H., Havlir, D. V., & Wood, R. (2012) · AIDS · doi:10.1097/qad.0b013e3283565dd1 · Cited by 55
“The limit of detection of this assay is 131 bacilli per ml of sputum [109], suggesting that TB cases undetected by this assay have low bacillary burdens in sputum and pose low infectious risk [60].”
BackgroundRyan, G. J., Shapiro, H. M., & Lenaerts, A. J. M. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.07.004 · Cited by 55
Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a diagnostic evaluation study
Tadesse, M., Abebe, G., Bekele, A., Bezabih, M., Yilma, D., Apers, L., de Jong, B. C., & Rigouts, L. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.12.018 · Cited by 55
Cost-effectiveness in the diagnosis of tuberculosis: choices in developing countries
Molicotti, P., Bua, A., & Zanetti, S. (2014) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.3295 · Cited by 54
“The most significant advance toward a molecular test for tuberculosis has come in the field of nucleic acid amplification with the launch of the GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, USA) [22].”
MethodBunsow, E., Ruiz‐Serrano, M. J., López-Roa, P., Kestler, M., de Viedma, D. G., & Bouza, E. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.11.012 · Cited by 54
Du, J., Huang, Z., Luo, Q., Xiong, G., Xu, X., Li, W., Liu, X., & Li, J. (2015) · PubMed Central · Cited by 54
Teo, J., Jureen, R., Chiang, D., Chan, D., & Lin, R. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00211-11 · Cited by 56
“tuberculosis and rifampin (RIF) resistance (1, 3, 5).”
BackgroundShah, N., Moodley, P., Babaria, P., Moodley, S., Ramtahal, M. A., Richardson, J. W., Heysell, S. K., Li, X., Moll, A. P., FRIEDLAND, G. H., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1449oc · Cited by 53
“Sensitivity may be improved slightly by performing multiple MODS assays, similar to other evaluations of rapid molecular tests on sputum.(36,37) Specificity has also been improved recently with revising of the MODS platform to include a microtitre well containing p-nnitrobenzoic acid (PNB), which specifically inhibits…”
MethodEngström, A., de la Torre, T. Z. G., Strømme, M., Nilsson, M., & Herthnek, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062015 · Cited by 53
Frugal Innovation for Point-of-Care Diagnostics Controlling Outbreaks and Epidemics
Miesler, T., Wimschneider, C., Brem, A., & Meinel, L. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01712 · Cited by 55
Youngquist, B. M., Saliba, J. G., Kim, Y., Cutro, T. J., Lyon, C. J., Olivo, J., Ha, N. P., Fine, J. M., Colman, R. E., Vergara, C. Z., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adp6411 · Cited by 54
Tan, Y., Hu, Z., Zhao, Y., Cai, X., Luo, C., Zou, C., & Liu, X. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05092-11 · Cited by 52
“There have been few data supporting this conjecture to this day because of a lack of characterization of rpoB mutations in Rfbr clinical Mycobacterium tuberculosis isolates, so it is very hard to identify the Rfbr isolates from RIFr isolates, even though so many molecular assays for prediction of rifampin susceptibili…”
BackgroundMolecular Basis of Drug Resistance in Mycobacterium tuberculosis
Cohen, K. A., Bishai, W. R., & Pym, A. S. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0036-2013 · Cited by 63
“tuberculosis complex as well as assay for RIF resistance (132).”
BackgroundFloridia, M., Ciccacci, F., Andreotti, M., Hassane, A., Sidumo, Z., Magid, N. A., Sotomane, H., David, M., Mutemba, E., Cebola, J., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix641 · Cited by 51
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
Bodmer, T., & Ströhle, A. (2012) · Journal of Visualized Experiments · doi:10.3791/3547 · Cited by 51
“The limit of detection lies at least two orders of magnitude lower than that of conventional microscopy.(6) Specificity is excellent.”
BackgroundMethodInfluentialCohen, G. M., Drain, P. K., Noubary, F., Cloete, C., & Bassett, I. V. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000309 · Cited by 50
“The WHO recommends Xpert machines be placed at the “health facility level (ideally district or subdistrict level),”(24) despite initial reports suggesting Xpert could be implemented at the clinical point-of-care.(7,25,26) In South Africa, Xpert has been placed in centralized laboratories, instead of peripheral health…”
BackgroundZiegenbalg, A., Prados‐Rosales, R., Jenny-Avital, E. R., Kim, R. S., Casadevall, A., & Achkar, J. M. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.03.001 · Cited by 50
Palud, P. L., Cattoir, V., Malbruny, B., Magnier, R., Campbell, K., Oulkhouir, Y., Zalcman, G., & Bergot, E. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-137 · Cited by 50
“If positive, the strain was categorized as susceptible or resistant to rifampicin [21,22].”
BackgroundComparison of culture, microscopic smear and molecular methods in diagnosis of tuberculosis.
Afşar, İ., Gunes, M., Er, H., & Şener, A. (2018) · PubMed Central · Cited by 50
Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis
Haraka, F., Kakolwa, M. A., Schumacher, S. G., Nathavitharana, R. R., Denkinger, C. M., Gagneux, S., Reither, K., & Ross, A. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012972.pub2 · Cited by 53
“Xpert MTB/RIF can detect MTBC and rifampicin resistance within two hours (Helb 2010).”
BackgroundWhole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance
Wang, L., Yang, J., Chen, L., Wang, W., Yu, F., & Xiong, H. (2022) · Epidemiology and Infection · doi:10.1017/s095026882100279x · Cited by 50
“Some rapid molecular biology-based diagnostic methods have recently been applied in a clinical setting, including Xpert MTB/RIF and GenoType MTBDRplus [2 – 4].”
Chakravorty, S., Kothari, H., Aladegbami, B. G., Cho, E. J., Lee, J. S., Roh, S. S., Kim, H., Kwak, H., Lee, E. G., Hwang, S. H., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00143-12 · Cited by 49
“When combined with automated sample processing systems, such as the Xpert MTB/RIF test (14), genotypic susceptibility tests can significantly reduce testing turnaround time, increasing patient notification rates and decreasing time to treatment (4, 32).”
MethodSelf-citationWalters, E. G., Goussard, P., Bosch, C., Hesseling, A. C., & Gie, R. P. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22970 · Cited by 49
“into the Xpert cartridge for processing by the Xpert machine as recommended by the manufacturer.(10) Lymph node tissue biopsy specimens were analyzed by histology, cytology, direct smear microscopy, and automated liquid culture.”
Method
Metadata
- Authors
- Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., Safi, H., Blakemore, R., Lan, N. T. N., Jones-López, E. C., Levi, M., Burday, M., Ayakaka, I., Mugerwa, R. D., McMillan, B., Winn-Deen, E., Christel, L., Dailey, P., Perkins, M. D., Persing, D. H., & Alland, D.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Cepheid (United States) (US)
- Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey
- FIND (CH)
- Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
- Montefiore Medical Center (US)
- Makerere University (UG)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 48
- Issue
- 1
- Pages
- 229-237
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2812290
- OpenAlex
- W2112022845
- Cited by
- 914
- References
- 59
- Citations by year
- 2026: 29 · 2025: 38 · 2024: 35 · 2023: 33 · 2022: 36 · 2021: 45 · 2020: 65 · 2019: 55 · 2018: 61 · 2017: 62 · 2016: 63 · 2015: 62 · 2014: 74 · 2013: 71 · 2012: 62
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R41AI052523, R42AI052523, R42-AI52523, R41-AI52523)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis detection, rifampicin resistance, Xpert MTB/RIF, point-of-care testing, real-time PCR, sputum, detection limit, nontuberculous mycobacteria, retreatment tuberculosis, tuberculosis diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Sputum, Tuberculosis, Uganda, Vietnam, Polymerase Chain Reaction, Point-of-Care Systems, Drug Resistance, Bacterial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.